As drug trafficking and the abuse of illicit drugs continue to inflict untold harm upon our society, it is clear that a global initiative and an intense domestic strategy are vital to address the sophisticated drug trafficking organizations (DTOs) that are prevalent in many regions. Covering a wide array of domestic interdiction topics, Drug Interd

Drug Law Enforcement Strategies provides an authoritative, insider's perspective on the intricacies of drug crimes, investigations, and trials. Featuring law enforcement officials from around the country, this book guides the reader through the latest trends in the narcotics arenaincluding new drugs entering the market, the medical marijuana controversy, and the role of technology in investigationswhile analyzing how these issues are impacting procedures. These skilled authors highlight proven methods for embarking on an investigation, creating drug-specific case strategies, working with informants, going undercover, and setting short- and long-term goals for an investigation. Looking at the investigator's role in bringing a drug case to court, they also explain how to supply effective evidence, work successfully with prosecutors, and anticipate questions from defense attorneys. Additionally, these leaders reveal their strategies for collaborating with other agencies, training investigators, and coping with shrinking budgets and limited manpower. The different niches represented and the breadth of perspectives presented enable readers to get inside some of the great legal minds of today, as these experienced officers offer up their thoughts on the keys to success within this ever-evolving field.

For nearly three decades, methadone hydrochloride has been the primary means of treating opiate addiction. Today, about 115,000 people receive such treatment, and thousands more have benefited from it in the past. Even though methadone's effectiveness has been well established, its use remains controversial, a fact reflected by the extensive regulation of its manufacturing, labeling, distribution, and use. The Food and Drug Administration regulates the safety and effectiveness of methadone, as it does for all drugs, and the Drug Enforcement Administration regulates it as a controlled substance. However, methadone is also subjected to a unique additional tier of regulation that prescribes how and under what circumstances it may be used to treat opiate addiction. Federal Regulation of Methadone Treatment examines current Department of Health and Human Services standards for narcotic addiction treatment and the regulation of methadone treatment programs pursuant to those standards. The book includes an evaluation of the effect of federal regulations on the provision of methadone treatment services and an exploration of options for modifying the regulations to allow optimal clinical practice. The volume also includes an assessment of alternatives to the existing regulations.

In this book, Horace Bartilow develops a theory of embedded corporatism to explain the U.S. government's war on drugs. Stemming from President Richard Nixon's 1971 call for an international approach to this "war," U.S. drug enforcement policy has persisted with few changes to the present day, despite widespread criticism of its effectiveness and of its unequal effects on hundreds of millions of people across the Americas. While researchers consistently emphasize the role of race in U.S. drug enforcement, Bartilow's empirical analysis highlights the class dimension of the drug war and the immense power that American corporations wield within the regime. Drawing on qualitative case study methods, declassified U.S. government documents, and advanced econometric estimators that analyze cross-national data, Bartilow demonstrates how corporate power is projected and embedded—in lobbying, financing of federal elections, funding of policy think tanks, and interlocks with the federal government and the military. Embedded corporatism, he explains, creates the conditions by which interests of state and nonstate members of the regime converge to promote capital accumulation. The subsequent human rights repression, illiberal democratic governments, antiworker practices, and widening income inequality throughout the Americas, Bartilow argues, are the pathological policy outcomes of embedded corporatism in drug enforcement.

Drug overdose, driven largely by overdose related to the use of opioids, is now the leading cause of unintentional injury death in the United States. The ongoing opioid crisis lies at the intersection of two public health challenges: reducing the burden of suffering from pain and containing the rising toll of the harms that can arise from the use of opioid medications. Chronic pain and opioid use disorder both represent complex human conditions affecting millions of Americans and causing untold disability and loss of function. In the context of the growing opioid problem, the U.S. Food and Drug Administration (FDA) launched an Opioids Action Plan in early 2016. As part of this plan, the FDA asked the National Academies of Sciences, Engineering, and Medicine to convene a committee to update the state of the science on pain research, care, and education and to identify actions the FDA and others can take to respond to the opioid epidemic, with a particular focus on informing FDA's development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring.